Stock TIL INSTIL BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Instil Bio, Inc.

Equities

TIL

US45783C2008

Delayed Nasdaq
Other stock markets
 01:29:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
10.4 USD -1.75% Intraday chart for Instil Bio, Inc. -5.97% +36.48%
Apr. 15 North American Morning Briefing : Stock Futures -2- DJ
Apr. 12 Jefferies Downgrades Instil Bio to Hold From Buy MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Stock Futures -2-
DJ
Jefferies Downgrades Instil Bio to Hold From Buy
MT
Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Instil Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Instil Bio Announces Strategic Update
AQ
Instil Bio, Inc. Enters into Agreement with A Collaboration to Conduct Preclinical Manufacturing Feasibility Studies in the ITIL-306 Program
CI
Instil Bio, Inc. Announces the Closure of Its UK Manufacturing and Clinical Operations
CI
Instil Bio, Inc.(NasdaqCM:TIL) dropped from NASDAQ Biotechnology Index
CI
Instil Bio Says 1-for-20 Reverse Stock Split to Take Effect on Dec. 7
MT
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
AQ
Instil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
AQ
Instil Bio, Inc.(NasdaqCM:TIL) dropped from S&P Global BMI Index
CI
Instil Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
HC Wainwright Initiates Instil Bio With Buy Rating, $2 Price Target
MT
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
AQ
Instil Bio, Inc. Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TIL Stock
  4. News Instil Bio, Inc.